LEGN Key Statistics, Chart & Performance
The current stock price of LEGN is 17.1 USD. In the past month the price decreased by -25.75%. In the past year, price decreased by -51.67%.
LEGN Technical Analysis
LEGN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LEGN. The financial health of LEGN is average, but there are quite some concerns on its profitability.
LEGN Financial Highlights
Over the last trailing twelve months LEGN reported a non-GAAP Earnings per Share(EPS) of -1.29. The EPS increased by 32.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.01% | ||
| ROE | -23.73% | ||
| Debt/Equity | 0.26 |
LEGN Forecast & Estimates
24 analysts have analysed LEGN and the average price target is 68.76 USD. This implies a price increase of 302.12% is expected in the next year compared to the current price of 17.1.
For the next year, analysts expect an EPS growth of -0.34% and a revenue growth 66.44% for LEGN
LEGN Ownership
LEGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 394.886B | ||
| AMGN | AMGEN INC | 17.06 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.1 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.99 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 13.22 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.54 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LEGN
Company Profile
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey and currently employs 2,900 full-time employees. The company went IPO on 2020-06-04. The firm is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. The company is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Company Info
LEGEND BIOTECH CORP-ADR
2101 Cottontail Lane
Somerset NEW JERSEY 08873 US
CEO: Ying Huang
Employees: 2600
Phone: 17328505598
LEGEND BIOTECH CORP-ADR / LEGN FAQ
What does LEGEND BIOTECH CORP-ADR do?
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey and currently employs 2,900 full-time employees. The company went IPO on 2020-06-04. The firm is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. The company is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Can you provide the latest stock price for LEGEND BIOTECH CORP-ADR?
The current stock price of LEGN is 17.1 USD. The price increased by 2.4% in the last trading session.
What is the dividend status of LEGEND BIOTECH CORP-ADR?
LEGN does not pay a dividend.
How is the ChartMill rating for LEGEND BIOTECH CORP-ADR?
LEGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists LEGN stock?
LEGN stock is listed on the Nasdaq exchange.
How is the market expecting LEGN stock to perform?
24 analysts have analysed LEGN and the average price target is 68.76 USD. This implies a price increase of 302.12% is expected in the next year compared to the current price of 17.1.
Can you provide the upcoming earnings date for LEGEND BIOTECH CORP-ADR?
LEGEND BIOTECH CORP-ADR (LEGN) will report earnings on 2026-03-09, after the market close.